AZD4635 + durvalumab + oleclumab

This item is a **triple combination therapy** consisting of AZD4635 (an orally available small-molecule antagonist of the adenosine A2A receptor), durvalumab (a human monoclonal antibody against programmed death-ligand 1, PD-L1), and oleclumab (a monoclonal antibody against CD73). AZD4635 blocks adenosine-mediated immunosuppression in the tumor microenvironment by antagonizing A2A receptors, potentially restoring T-cell activity. Durvalumab inhibits the interaction between PD-L1 and PD-1, promoting T-cell activation and anti-tumor immunity. Oleclumab inhibits CD73, an ectoenzyme involved in conversion of AMP to adenosine, further abrogating adenosine-mediated immunosuppression. This triple combination is mainly under investigation for metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors, aiming to synergistically target immunosuppressive mechanisms within the tumor microenvironment to enhance anti-tumor immune responses[3][4].

Brand names

Imfinzi (durvalumab)

Other names

AZD4635 plus durvalumab plus oleclumabAZD-4635 plus durvalumab plus oleclumabAZD 4635 plus durvalumab plus oleclumab